A Dark Vector Cognition product

Item 6. Exhibits

3K characters. Original on sec.gov ·

Item 6. Exhibits

The 2 tables in Item 6. Exhibits as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Exhibit NumberExhibit Description
10.1Revolving Credit Agreement, dated as of July 30, 2026, by and among Vertex Pharmaceuticals Incorporated, Bank of America, N.A., and other lenders party thereto.
10.2Term Loan Agreement, dated as of July 30, 2026, by and among Vertex Pharmaceuticals Incorporated, Bank of America, N.A., and other lenders party thereto.
10.3Employment Agreement, dated as of August 31, 2026, by and between Vertex Pharmaceuticals Incorporated and Jonathan Poole.*
10.4Change of Control Agreement, dated as of August 31, 2026, between Vertex Pharmaceuticals Incorporated and Jonathan Poole.*
31.1Certification of the Chief Executive Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
31.2Certification of the Chief Financial Officer under Section 302 of the Sarbanes-Oxley Act of 2002.
32.1Certification of the Chief Executive Officer and the Chief Financial Officer under Section 906 of the Sarbanes-Oxley Act of 2002.
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*Management contract, compensatory plan or agreement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be

signed on its behalf by the undersigned thereunto duly authorized.

Vertex Pharmaceuticals Incorporated
November 3, 2026By:/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Operating & Financial Officer (principal financial officer and duly authorized officer)

Previous: Item 5. Other Information